Feb 17, 2015, 00:00
by
Michael Croft
CHAPEL HILL, NC, UNITED STATES - Feb 17, 2015 - Rho, a contract research organization (CRO) focused on bringing new products to market through a full range of product development services, offers tips and considerations for implementing electronic patient reported outcomes (ePRO) on tablet devices, based on a recent application in a large phase 3 pain study
CHAPEL HILL, NC, UNITED STATES - Feb 17, 2015 - Rho, a contract
research organization (CRO) focused on bringing new products to
market through a full range of product development services, offers
tips and considerations for implementing electronic patient
reported outcomes (ePRO) on tablet devices, based on a recent
application in a large phase 3 pain study.
ePRO can be a challenge to implement, but often provides higher
quality data, said Emily Cantrell, senior director of operations
for Rho. Our study was a pivotal study, and we used an ePRO
system to collect our primary endpoint - with devices kept at sites
and data entered only during study visits - which provided many
learning opportunities for our implementation team.
Key considerations for implementing ePRO and smart devices from
Rho include:
- Validation:
- Depending on the stage of development your study is in, and if
ePRO will be used to record the primary endpoint, validation may be
required.
- In the Rho example, data was collected to measure pain on a
visual analog scale (VAS), and the scale was validated by recording
results on tablets, on paper and via an interview, with results
compared to determine the validity of the tablet questions.
- If validation is required, a third-party vendor is often used,
which can increase costs significantly, so be sure to budget
accordingly.
- Study Start-up and Site Issues:
- Before beginning the trial, technology at each site must be
evaluated - from available and reliable WiFi connections to
firewall considerations.
- Confirm storage at each site and set up charging stations to
maintain battery life of each device, preventing loss of data
in the event of battery failure prior to sending data.
- Train the study team, site staff and investigators to ensure
comfort with the tablet, accessories and software, as well as
username and password rules - for audit and trial compliance
purposes, it is important that each team member has and uses their
own password.
- Determine a back-up system in case something goes wrong - a
paper system must be identical to the ePRO system, including
language options.
- Review bids carefully to ensure all study needs are covered -
validation, support time, extra devices to serve as backups,
etc.
- Ask for specification of devices and accessories, including
plans to change or upgrade devices during the course of the
study.
- Be involved in user acceptance testing (UAT) for the device,
and dont be afraid to test other scenarios to confirm the device
is working appropriately.
- Choose a method for handling support - technical support
through the vendor or frontline support through your own client
support call center.
- Ask for vendor recommendations from trusted site staff who may
have previous experience with various systems.
This process provided a unique learning opportunity for our
team, added Cantrell. The quality of the data, and duration and
scope of the study made ePRO a good choice for our study, and we
look forward to applying the lessons learned for future customer
studies.
To learn more about Rho, please visit www.rhoworld.com.
About Rho
Rho, a privately-held, contract research organization (CRO)
located in Chapel Hill, NC, provides a full range of clinical
research services across the entire drug development process. For
more than 25 years, Rho has been a trusted partner to some of the
industrys leading pharmaceutical, biotechnology, and medical
device companies as well as academic and government organizations.
Our commitment to excellence, our innovative technologies, and our
therapeutic expertise accelerate time to market, maximize returns
on investment, and lead to an exceptional customer experience.
Please follow us on Twitter.
###